1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 52, n° 6
pages 967-971 (juin 2005)
Doi : 10.1016/j.jaad.2005.01.020
accepted : 10 January 2005

Extent and impact of industry sponsorship conflicts of interest in dermatology research

Clifford S. Perlis, MD, Michael Harwood, BS, Roy H. Perlis, MD
From the Department of Dermatology, Rhode Island Hospital and Brown Medical School, and the Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School 

Reprint requests: Roy H. Perlis, MD, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman St WACC 812, Boston, MA 02114.

Providence, Rhode Island, and Boston, Massachusetts


Many published clinical trials are authored by investigators with financial conflicts of interest. The general medical literature documents the pervasive extent and sometimes problematic impact of these conflicts. Accordingly, there is renewed discussion about author disclosure and clinical trial registry to minimize publication bias from financial conflicts of interest. Despite this evolving discussion in the general medical literature, little is known about the extent or role of financial conflicts of interest in dermatology research.


Our purpose was to determine the extent and impact of industry sponsorship conflicts of interest in dermatology research.


We recorded potential financial conflicts of interest, study design, and study outcome in 179 clinical trials published between Oct 1, 2000 and Oct 1, 2003 in four leading dermatology journals.


Forty-three percent of analyzed studies included at least one author with a reported conflict of interest. These studies were more likely to report a positive result, demonstrate higher methodological quality, and include a larger sample size.


Conflict of interest in clinical investigations in dermatology appears to be prevalent and associated with potentially significant differences in study methodology and reporting.

The full text of this article is available in PDF format.

 Funding sources: None.
Disclosure: Dr C. Perlis and Mr Harwood have no conflicts of interest to disclose. Dr R. Perlis has served on advisory boards for, or received speaker's fees or honoraria from, the following companies: AstraZeneca, BMS, Eli Lilly and Co, GlaxoSmithKline, and Pfizer. Dr R. Perlis has received research support from the following companies: AstraZeneca, Eli Lilly and Co, and Elan/Eisai; and is supported by an NIMH K23 Career Development Award.

© 2005  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline